

Project scope: Transcatheter Aortic Valve Implantation (TAVI)

June 2024

Research question

1. What is the clinical effectiveness, cost effectiveness, safety and patient perspectives of transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) for the treatment of people with severe symptomatic aortic stenosis who are at intermediate-to-low surgical risk?

Inclusion criteria

The selection of studies for inclusion in the literature review element of the project will be based on the following criteria:

Population	Adults Severe symptomatic aortic stenosis Intermediate-to-low surgical risk
Intervention/exposure	Transcatheter aortic valve implantation (TAVI) Transcatheter aortic valve replacement (TAVR)
Comparator	Surgical aortic valve replacement (SAVR)
Outcomes	Mortality Symptom reduction Aortic valve re-intervention Valve function Health related quality of life Adverse events Stroke Vascular complications Patient experiences, preferences, views etc Cost effectiveness

Planned activities

SHTG have agreed on the following activities to support an SHTG Assessment on TAVI compared with SAVR in people with severe symptomatic aortic stenosis and intermediate-to-low surgical risk:

1. A literature review and summary of the clinical effectiveness, cost effectiveness, safety and patient aspects evidence.
2. A peer review exercise to gather feedback from topic experts on the evidence summary.
3. Engagement with clinical experts through peer review.

End products

At the end of the project, SHTG will publish:

- An SHTG Assessment.
- A plain language summary of the SHTG Assessment.

Timescales (approximate)

The SHTG Assessment will be published on the SHTG website in October 2024.